RIO DE JANEIRO, BRAZIL – The development of a Brazilian vaccine against Covid-19 at the Vaccine Technology Center of the Federal University of Minas Gerais (UFMG) will take another step forward.
Scientists involved in developing the vaccine will deliver a report to the national health regulatory agency (Anvisa) to start human trials.
The report is to be delivered to Anvisa on Friday (30). If the documents are approved, Spintec will be tested in humans in two phases: The first will enroll 30 to 40 subjects and the second 150 to 300 subjects.